Next Article in Journal
Beyond Gene Delivery: Strategies to Engineer the Surfaces of Viral Vectors
Biomedicines 2013, 1(1), 1-2; doi:10.3390/biomedicines1010001

Biomedicines—Moving Biologic Agents into Approved Treatment Options

Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 W, Walnut Street Room 130, Indianapolis, IN 46202, USA
Received: 8 March 2013 / Accepted: 8 March 2013 / Published: 11 March 2013
View Full-Text   |   Download PDF [96 KB, 14 March 2013; original version 11 March 2013]
Note: In lieu of an abstract, this is an excerpt from the first page.


The development of biologic agents for therapeutic purposes, or biomedicines, has seen an active area of research both at the bench and in clinical trials. There is mounting evidence that biologic products can provide effective therapy for diseases that have been unresponsive to traditional pharmacologic approaches. Monoclonal antibody therapy for cancer and rheumatologic diseases has become a well accepted part of disease treatment plans. Gene therapy products have been approved in China and Europe. Bioengineering of new agents capitalizing on microRNA biology, nanoparticle technology, stem cell biology, and an increasing understanding of immunology predict a rich future for product development. [...]
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Cornetta, K. Biomedicines—Moving Biologic Agents into Approved Treatment Options. Biomedicines 2013, 1, 1-2.

View more citation formats

Related Articles

Article Metrics


[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert